Supernus Pharma (SUPN) Reports Q4 Revenue of $155M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Join SI Premium – FREE
Supernus Pharma (NASDAQ: SUPN) reported Q4 revenue of $155 million versus the consensus estimate of $149.42 million.
GUIDANCE:
Supernus Pharma sees FY2022 revenue of $640-680 million, versus the consensus of $707.32 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
- Regal-Beloit (RBC) Tops Q3 EPS by 21c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
